Newsroom

March 16, 2026

Amlogenyx Announces Positive Preclinical Data on AM805, a Potent Amyloid-Degrading Protease for the Treatment of Alzheimer’s Disease

Novel and potent catalytic approach that directly clears amyloid on the inside of neurons as well as reduces amyloid plaques with the potential to be superior to monoclonal antibodies and restore neuronal function while halting or reversing disease progression.

Read more

August 11, 2025

Amlogenyx Announces Expansion of Board of Directors and Formation of Scientific Advisory Board

Advancing a novel gene therapy to treat Alzheimer’s disease. Appointed three Alzheimer’s experts to newly formed Scientific Advisory Board. Gene therapy expertise enhanced on the board of directors with a new Independent member.

Read more